Definition And Electrophysiology
- Supra-ventricular tachycardia (SVT) encompasses paroxysmal or incessant tachycardias originating above or within the His bundle, excluding ventricular tachycardia.
- Characterized by a narrow QRS complex, defined as <120 ms in adolescents and young adults, <100 ms in children, and typically <0.08 seconds in neonates.
- Fetal SVT is characterized by sustained rates >220 beats/min with 1:1 atrioventricular (AV) conduction.
Arrhythmia Mechanisms And Subtypes
SVT is driven by two primary electrophysiological mechanisms: reentry and abnormal automaticity.
| Mechanism | Electrophysiological Characteristics | Common Clinical Examples |
|---|---|---|
| Reentry | Requires two distinct pathways, a zone of conduction delay, and unidirectional block. Characterized by abrupt onset and termination with a regular cycle length. | Atrioventricular Reciprocating Tachycardia (AVRT), Atrioventricular Nodal Reentry Tachycardia (AVNRT), Atrial Flutter. |
| Abnormal Automaticity | Ectopic focus drives depolarization. Characterized by gradual acceleration (warm-up) and gradual deceleration (cool-down). | Ectopic Atrial Tachycardia (EAT), Junctional Ectopic Tachycardia (JET). |
Specific Arrhythmia Syndromes
- Atrioventricular Reciprocating Tachycardia (AVRT): Most common SVT mechanism in infants, utilizing an accessory bypass tract. Orthodromic AVRT (antegrade AV node, retrograde pathway) yields a narrow QRS, while antidromic AVRT (antegrade pathway, retrograde AV node) yields a wide QRS.
- Atrioventricular Nodal Reentry Tachycardia (AVNRT): Utilizes dual functional pathways (fast and slow) within the AV node. Rare in infancy but common in adolescence.
- Atrial Flutter: A macro-reentrant circuit within the atria. Common in neonates with normal hearts or older children with surgically stretched atria (e.g., Fontan procedure, Ebstein anomaly).
- Junctional Ectopic Tachycardia (JET): Automatic focus near the His bundle, most commonly occurring postoperatively after congenital heart surgery due to surgical trauma or edema.
Clinical Presentation
Neonates And Infants
- Unrecognized SVT for 6β24 hours may present with signs of heart failure.
- Symptoms include poor feeding, ashen color, restlessness, irritability, tachypnea, and hepatomegaly.
- Heart rates typically range from 240β300 beats/min.
Older Children And Adolescents
- Present with abrupt onset of palpitations, precordial discomfort, fatigue, dizziness, dyspnea, or syncope.
- Heart rates are typically >180 beats/min.
- Episodes may be exacerbated by extrinsic triggers such as caffeine or nonprescription decongestants.
Fetal Presentation
- Fetal SVT can cause in utero heart failure leading to hydrops fetalis.
- Mortality approaches 50% without effective antiarrhythmic treatment.
Diagnostic Evaluation
Electrocardiography Features
- SVT exhibits fixed, rapid rates lacking the normal beat-to-beat variability seen in sinus tachycardia.
- P waves are visible in only 50β60% of neonates on a standard ECG, often hidden within the QRS or T wave.
- An abnormal P-wave axis (e.g., inverted in leads II, III, and aVF) strongly suggests SVT and argues against sinus tachycardia.
- A transesophageal lead can effectively detect P waves when the surface ECG is obscure.
Differential Diagnosis: Narrow QRS Tachycardia
| Arrhythmia | P-Wave Characteristics | P-QRS Relationship | Response To Adenosine Challenge |
|---|---|---|---|
| Sinus Tachycardia | Normal morphology and axis | 1:1 | Transient slowing; transient AV block. |
| Ectopic Atrial Tachycardia | Abnormal, different from baseline | Usually 1:1 | No effect on rate; transient AV block unmasks abnormal atrial activity. |
| Atrial Flutter | Saw-tooth appearance (>240/min) | 2:1 or 1:1 | Transient AV block unmasks underlying flutter waves; rarely terminates. |
| AVNRT / AVRT | Usually not visible or inverted | 1:1 | Abrupt termination. |
| Junctional Ectopic (JET) | Normal or inverted | AV dissociation diagnostic | No effect on rate; transient retrograde VA block. |
Management Strategies
Acute Termination
- Vagal Maneuvers: First-line non-pharmacological therapy for stable patients. Application of an ice bag to the entire face for 15β30 seconds in infants, or Valsalva maneuver in older children. Ocular pressure is strictly contraindicated.
- Adenosine: Drug of choice for stable patients with AVRT or AVNRT. Administered as a rapid IV push of 0.1 mg/kg (up to 6 mg initial dose), increasing to 0.2 mg/kg (up to 12 mg) if ineffective. Must be followed by a rapid saline flush. Contraindicated in asthma/bronchospastic disease or without direct current (DC) cardioversion standby.
- DC Cardioversion: Indicated immediately for hemodynamically unstable patients or those in urgent heart failure. Administered as a synchronized shock at 0.5β2 J/kg.
Chronic Pharmacotherapy
| Medication | Class | Clinical Indications And Nuances |
|---|---|---|
| Beta-Blockers (Propranolol, Atenolol) | Class II | Mainstay chronic suppression for patients without antegrade accessory pathways (Non-WPW). |
| Digoxin | Class V | Effective first-line therapy in infants. Strictly contraindicated in WPW syndrome due to risk of rapid antegrade accessory pathway conduction precipitating ventricular fibrillation. |
| Verapamil | Class IV | Utilized in older children. Strictly contraindicated in infants <1 year due to profound bradycardia, hypotension, severe apnea, and cardiovascular collapse risk. Contraindicated in WPW. |
| Amiodarone / Sotalol / Flecainide | Class III / IC | Indicated for resistant or refractory SVT. Flecainide is strictly restricted to patients with structurally normal ventricular function. |
Definitive Therapy
- Catheter Ablation: Definitive, potentially curative therapy utilizing radiofrequency or cryoablation. Cryoablation is preferred near the AV node to eliminate permanent heart block risk.
- Success Rates: 90β98% depending on the pathway location.
- Indications: Ventricular dysfunction, medically refractory SVT, avoidance of long-term medication, hemodynamic compromise during SVT, or WPW with syncope/resuscitated cardiac arrest.
- Complications: AV block, perforation, thrombosis, with a higher incidence in children weighing <15 kg.
Fetal SVT Management
- Maternal Transplacental Therapy: First-line treatment for fetal SVT without hydrops. Digoxin (targeting maternal trough 1.5β2.0 mcg/mL), flecainide, and sotalol are the most common agents utilized. Flecainide exhibits a highly successful conversion rate.
- Hydropic Fetus: Reduced transplacental bioavailability necessitates combination therapy or alternative routes. Direct fetal intramuscular (IM) digoxin injection into the buttock or thigh rapidly decreases the time to conversion, effectively bypassing placental transfer issues. Amiodarone may be required for severe, refractory hydropic cases.